Septerna to Present at TD Cowen 45th Annual Health Care Conference
Septerna (Nasdaq: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in an upcoming investor event.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Septerna (Nasdaq: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in an upcoming investor event. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation at the TD Cowen 45th Annual Health Care Conference in Boston.
The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET. This conference appearance represents an opportunity for Septerna to showcase its innovative GPCR drug discovery platform to the investment community.
Details
News Market Reaction – SEPN
The recorded move for SEPN in the trading session of this news was +3.26%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston.
About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.